齐拉西酮与奋乃静治疗儿童期首发精神分裂症对照研究  

A clinical study of ziprasidone vs perphenazine in the treatment of childhood patients with first-episode schizophrenia

作　　者：宋丽[1] 余学[1] 郭平[1] 

机构地区：[1]河南省驻马店市精神病医院,河南驻马店463000

出　　处：《中国当代医药》2010年第35期24-25,共2页China Modern Medicine

摘　　要：目的:比较齐拉西酮与奋乃静对儿童期首发精神分裂症治疗的临床疗效和安全性。方法:将80例儿童期首发精神分裂症患儿随机分为研究组和对照组,每组各40例,研究组给予齐拉西酮治疗,对照组给予奋乃静治疗,观察8周。于治疗前和治疗后2、4、6、8周末,以阳性与阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评价安全性。结果:两组PANSS总分在治疗后与治疗前比较差异有统计学意义(P<0.01),但齐拉西酮起效快。临床总有效率齐拉西酮为87.5%,奋乃静为80.0%,组间比较差异无统计学意义(P>0.05)。齐拉西酮较奋乃静不良反应小。结论:齐拉西酮治疗儿童期首发精神分裂症疗效较好,安全性高。Objective： To compare ziprasidone and perphenazine in the treatment of children of first-episode schizophrenia clinical efficacy and safety. Methods： 80 cases of childhood schizophrenia were randomly divided into study group and control group, 40 patients in each group, study group received ziprasidone treatment, control group was given perphenazine treatment were observed for 8 weeks. Before and after treatment in the treatment of 2,4,6,8 weekend to positive and negative syndrome scale （PANSS） to assess the clinical scale with side effects （TESS） evaluation of safety. Results： PANSS total score after treatment compared with before treatment difference was statistically significant （P0.01）, but with rapid onset of ziprasidone. The total effective rate was 87.5% of ziprasidone, perphenazine, 80.0%, group no significant difference between （P0.05）. Ziprasidone side effects compared with perphenazine. Conclusion： Ziprasidone treatment of children with good effect of first-episode schizophrenia and safe.

关 键 词：齐拉西酮 奋乃静 首发精神分裂症 儿童 疗效 

分 类 号：R749.3[医药卫生—神经病学与精神病学]